Landos Biopharma provides update on clinical development plans

Landos Biopharma announced a comprehensive update on its future clinical development plans. "After thorough analysis and careful consideration, we are confident that focusing our resources toward NX-13’s clinical development has the potential to deliver the most value for Landos and our shareholders," said Gregory Oakes, President and Chief Executive Officer of Landos. "…We expect that the NX-13 Phase 2 trial will have two active arms and will be blinded, placebo-controlled, and statistically powered. We have already completed a series of startup activities and are on track for first site activation and patient enrollment in the second quarter of 2023. We look forward to sharing our progress and expect to report topline data by the fourth quarter of 2024." Clinical Stage Programs: NX-13 – Landos will be conducting a Phase 2 proof-of-concept clinical trial for NX-13, which will be dose ranging, blinded, placebo-controlled, and statistically powered. The Company is on track for first site activation and patient enrollment for the NX-13 Phase 2 trial in the second quarter of 2023. The Company expects to report topline data from the trial by the fourth quarter of 2024. In addition to UC, the Company believes NX-13 has the potential to treat CD. Omilancor – The Company is evaluating whether an enhanced formulation may improve absorption and local bioavailability of Omilancor to the colonic mucosa, and potentially increasing durable efficacy. LABP-104 – Today, Landos announced that it recently completed a successful Phase 1a clinical trial of LABP-104, which was well-tolerated in healthy volunteers and did not result in any serious adverse events. The Phase 1a clinical trial results for LABP-104 support its potential as a treatment for SLE and/or RA, and the Company is evaluating whether future formulations may provide enhanced absorption characteristics to maximize drug effects. Pre-Clinical Programs: LABP-66: As announced in August 2021, Landos entered into a research collaboration with Dr. Peter Calabresi, Director of the Multiple Sclerosis Center and Professor of Neurology at Johns Hopkins University School of Medicine. The research is funded by the National Institute of Health and is focused on further validating the NLRX1 immunometabolic pathway in MS. LABP-73: A novel NLRX1 agonist in development for the treatment of Asthma and Chronic Obstructive Pulmonary Disease. LABP-69: A novel PLXCD2 agonist in development for the treatment of RA and Diabetic Nephropathy. LABP-111: A novel LANCL2 agonist in development for the treatment of NASH and Diabetes.